Investors target Chinese cancer drugs

Drug developers such as I-Mab are trying to lead the market and secure future cash flow with their technological progress.

The search for anti-cancer drugs has strong support from the Chinese government which has spurred investors to pour money into the sector. What's hot this year seems to be immuno-oncology and the related field of precision medicine.

Traditional chemotherapy indiscriminately attacks cells, whether they are cancerous or not. But more advanced oncology treatments seek to activate a body's own immune system to destroy cancer cells. This is called immuno-oncology I-O, which is more efficient and has fewer side effects.

It is becoming an investment focus for 2019, according to Kevin Xie, co-founder and head of the healthcare advisory team at China Renaissance.


¬ Haymarket Media Limited. All rights reserved.

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222